

Chih-Hung Hsu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7418153/publications.pdf>

Version: 2024-02-01

172
papers

7,816
citations

94433

37
h-index

62596

80
g-index

173
all docs

173
docs citations

173
times ranked

9471
citing authors

#	ARTICLE	IF	CITATIONS
1	Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer. Journal of the Formosan Medical Association, 2023, 122, 4-8.	1.7	4
2	Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1803-1811.	2.5	2
3	Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. Journal of Clinical Oncology, 2022, 40, 279-279.	1.6	1
4	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 2022, 386, 449-462.	27.0	419
5	Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head&neck cancer. Cancer Medicine, 2022, 11, 2550-2560.	2.8	25
6	Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. Journal of Clinical Oncology, 2022, 40, e16107-e16107.	1.6	0
7	Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.. Journal of Clinical Oncology, 2022, 40, 4035-4035.	1.6	3
8	Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nature Medicine, 2022, 28, 1599-1611.	30.7	185
9	Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma. Journal of the Formosan Medical Association, 2021, 120, 559-566.	1.7	24
10	It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade. Journal of the Formosan Medical Association, 2021, 120, 1-4.	1.7	8
11	Solving the deficit of cancer pain management skills by education programs. Supportive Care in Cancer, 2021, 29, 1843-1848.	2.2	2
12	Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites. Oncology, 2021, 99, 652-658.	1.9	2
13	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British Journal of Cancer, 2021, 124, 1388-1397.	6.4	39
14	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. Journal of the Chinese Medical Association, 2021, 84, 144-150.	1.4	8
15	An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma. Oncologist, 2021, 26, 422-426.	3.7	8
16	Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma. Diagnostics, 2021, 11, 1340.	2.6	6
17	Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma. Cells, 2021, 10, 1698.	4.1	5
18	An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 809-822.	3.7	17

#	ARTICLE	IF	CITATIONS
19	Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. <i>Experimental Hematology and Oncology</i> , 2021, 10, 45.	5.0	19
20	Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 16, 100255.	2.9	5
21	Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. <i>Cancers</i> , 2021, 13, 5142.	3.7	2
22	Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials. <i>Cancers</i> , 2021, 13, 4962.	3.7	3
23	A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 99-110.	2.6	41
24	Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 565-568.	1.7	16
25	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	1.6	614
26	Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. <i>Liver Cancer</i> , 2020, 9, 440-454.	7.7	10
27	The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. <i>Journal of the Formosan Medical Association</i> , 2020, 120, 1581-1590.	1.7	4
28	Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2020, 21, 808-820.	10.7	371
29	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 122, 1324-1332.	6.4	23
30	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. <i>Oncologist</i> , 2020, 25, e1280-e1285.	3.7	14
31	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. <i>Liver Cancer</i> , 2019, 8, 110-120.	7.7	46
32	Early alpha-fetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. <i>Liver International</i> , 2019, 39, 2184-2189.	3.9	55
33	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 480-490.	7.7	57
34	Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. <i>Anticancer Research</i> , 2019, 39, 5675-5682.	1.1	30
35	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1506-1517.	10.7	767
36	Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1433.	3.7	13

#	ARTICLE	IF	CITATIONS
37	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 615-621.	3.0	5
38	Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. Journal of Hepatocellular Carcinoma, 2019, Volume 6, 71-84.	3.7	54
39	Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment. European Journal of Surgical Oncology, 2019, 45, 1498-1504.	1.0	9
40	Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Journal of the Formosan Medical Association, 2019, 118, 1024-1030.	1.7	5
41	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.. Journal of Clinical Oncology, 2019, 37, 4010-4010.	1.6	38
42	Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.. Journal of Clinical Oncology, 2019, 37, 2-2.	1.6	136
43	Activated interferon- γ (IFN- γ) pathway associated with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2019, 37, 67-67.	1.6	0
44	Targeting tumor-infiltrating Ly6G ⁺ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma. International Journal of Cancer, 2018, 142, 1878-1889.	5.1	46
45	Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma. Journal of Thoracic Oncology, 2018, 13, e36-e39.	1.1	5
46	Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure. Liver Cancer, 2018, 7, 205-208.	7.7	4
47	Validation of the postneoadjuvant therapy pathological stage of the American Joint Committee on Cancer (AJCC) 8th Edition for predicting outcomes of esophageal squamous cell carcinoma (ESCC) patients receiving neoadjuvant chemoradiotherapy (CRT) followed by esophagectomy.. Journal of Clinical Oncology, 2018, 36, 138-138.	1.6	0
48	The prognostic impact of neutrophil to lymphocyte ratio in patients with recurrent or metastatic esophageal squamous cell carcinoma receiving immune checkpoint inhibitors.. Journal of Clinical Oncology, 2018, 36, 69-69.	1.6	0
49	Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy. Anticancer Research, 2018, 38, 1569-1577.	1.1	9
50	Response to immune checkpoint inhibitors in recurrent/metastatic esophageal squamous cell carcinoma may be affected by tumor site and lesion size.. Journal of Clinical Oncology, 2018, 36, e16099-e16099.	1.6	0
51	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemotherapy and Pharmacology, 2017, 79, 421-429.	2.3	19
52	National Policies Fostering Hospice Care Increased Hospice Utilization and Reduced the Invasiveness of End-of-Life Care for Cancer Patients. Oncologist, 2017, 22, 843-849.	3.7	19
53	A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement. Journal of the Formosan Medical Association, 2017, 116, 689-696.	1.7	9
54	Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. European Radiology, 2017, 27, 3069-3079.	4.5	18

#	ARTICLE	IF	CITATIONS
55	Right or left? Side selection for a totally implantable vascular access device: a randomised observational study. <i>British Journal of Cancer</i> , 2017, 117, 932-937.	6.4	13
56	High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 949-953.	1.3	37
57	Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells. <i>Oncotarget</i> , 2017, 8, 86681-86692.	1.8	11
58	Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study. <i>Anticancer Research</i> , 2017, 37, 2593-2599.	1.1	17
59	A phase II study of early FDG-PET evaluation after one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy: Final report.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4042-4042.	1.6	14
60	On predicting clinical response to chemoradiotherapy in esophageal squamous cell carcinoma: additional evaluation by magnetic resonance imaging may help. <i>Annals of Translational Medicine</i> , 2017, 5, 487-487.	1.7	0
61	Inhibition of the Wnt/ β -catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. <i>Cancer Letters</i> , 2016, 381, 58-66.	7.2	39
62	Key opioid prescription concerns in cancer patients: A nationwide study. <i>Acta Anaesthesiologica Taiwanica</i> , 2016, 54, 51-56.	1.0	9
63	Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges. <i>Liver Cancer</i> , 2016, 5, 128-138.	7.7	108
64	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1336-1341.	2.8	25
65	Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy. <i>Radiology</i> , 2016, 281, 454-464.	7.3	33
66	Effect of national policy changes on hospice utilization and the invasiveness of end-of-life care in cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10008-10008.	1.6	1
67	Tumor-associated neutrophils: an emerging player in the immune microenvironment of hepatocellular carcinoma. <i>Translational Cancer Research</i> , 2016, 5, S296-S299.	1.0	2
68	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 7275.	3.3	26
69	The recurrence patterns and post-recurrence survivals in patients with locally advanced esophageal squamous cell carcinoma (ESCC) treated with preoperative paclitaxel/cisplatin-based chemoradiotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 80-80.	1.6	0
70	Low-dose nab-paclitaxel-based combination chemotherapy in heavily-pretreated pancreatic or ampullary cancer patients: Taiwanese single-center case series.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15695-e15695.	1.6	0
71	Association of the number of dissected lymph node (LN) with the survivals of locally advanced esophageal squamous cell carcinoma (ESCC) patients received preoperative chemoradiotherapy (CRT) followed by surgery.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15543-e15543.	1.6	0
72	High Serum Transforming Growth Factor- β 1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib. <i>Clinical Cancer Research</i> , 2015, 21, 3678-3684.	7.0	76

#	ARTICLE	IF	CITATIONS
73	Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1481-1489.	1.1	15
74	Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials. <i>Oncology</i> , 2015, 88, 345-352.	1.9	31
75	Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2015, 115, 9-15.	0.6	12
76	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. <i>Clinical Colorectal Cancer</i> , 2015, 14, 177-184.e4.	2.3	36
77	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2015, 26, 943-949.	1.2	130
78	Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1527-1545.	3.8	71
79	Serum Transforming Growth Factor- β 1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1023-1031.	0.8	2
80	Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1023-1028.	1.3	33
81	Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?. <i>World Journal of Gastroenterology</i> , 2015, 21, 10336.	3.3	38
82	Postchemoradiotherapy (CRT) pathologic stage classified by American Joint Committee on Cancer (AJCC) staging system to predict prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 158-158.	1.6	0
83	Tumor c-Met expression and prognosis of advanced hepatocellular carcinoma patients treated with sorafenib.. <i>Journal of Clinical Oncology</i> , 2015, 33, 317-317.	1.6	0
84	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. <i>Journal of Hepatocellular Carcinoma</i> , 2014, 1, 85.	3.7	17
85	β -Catenin (CTNNB1) Mutations Are Not Associated with Prognosis in Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2014, 87, 159-166.	1.9	35
86	Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 577-578.	1.7	4
87	Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. <i>Journal of Hepatology</i> , 2014, 60, 313-318.	3.7	47
88	Clinical Activity of Metronomic Chemotherapy in Liver Cancers. , 2014, , 189-202.		0
89	Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4100-4100.	1.6	0
90	Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS2631-TPS2631.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy. <i>Anticancer Research</i> , 2014, 34, 1047-52.	1.1	8
92	Clinical Trials in Hepatocellular Carcinoma: An Update. <i>Liver Cancer</i> , 2013, 2, 345-364.	7.7	58
93	Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3517-3524.	1.6	675
94	Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?. <i>Liver Cancer</i> , 2013, 2, 93-107.	7.7	35
95	A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy. <i>Liver International</i> , 2013, 33, 1413-1419.	3.9	15
96	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma. <i>Cancer</i> , 2013, 119, 1210-1216.	4.1	13
97	Nuclear Expression of Glioma-Associated Oncogene Homolog 1 and Nuclear Factor- κ B Is Associated with a Poor Prognosis of Pancreatic Cancer. <i>Oncology</i> , 2013, 85, 86-94.	1.9	23
98	Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study. <i>Oncology</i> , 2013, 85, 44-52.	1.9	46
99	The Germline BIM Deletion Polymorphism Is Not Associated with the Treatment Efficacy of Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 85, 312-316.	1.9	6
100	Regular statin users and colorectal cancer (CRC) prognosis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3554-3554.	1.6	1
101	Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4099-4099.	1.6	1
102	Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size. <i>PLoS ONE</i> , 2013, 8, e80276.	2.5	23
103	Unique histopathologic features of brain metastases from hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 169-169.	1.6	0
104	Prevalence of gene amplifications of SOX-2, c-MET, and FGFR1 in Asian patients with esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15127-e15127.	1.6	0
105	Clinicopathologic features and treatment outcome of primary intestinal non-Hodgkin lymphoma: A single center experience.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19523-e19523.	1.6	0
106	Survival of patients receiving radiofrequency ablation or ethanol injection for early-stage hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15043-e15043.	1.6	0
107	Vascular endothelial growth factor expression in hepatitis C virus (HCV)-related advanced hepatocellular carcinoma (HCC) compared with hepatitis B virus (HBV)-related advanced HCC.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4115-4115.	1.6	8
108	Clinical features of long-term survivors (LTS) of advanced hepatocellular carcinoma undergoing molecular targeted therapy (MTT).. <i>Journal of Clinical Oncology</i> , 2013, 31, e15182-e15182.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy. <i>Anticancer Research</i> , 2013, 33, 4123-8.	1.1	9
110	Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 3992-3997.	7.0	41
111	Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma. <i>Oncologist</i> , 2012, 17, 856-862.	3.7	32
112	Factors Impacting Prognosis Prediction in BCLC Stage C and Child-Pugh Class A Hepatocellular Carcinoma Patients in Prospective Clinical Trials of Systemic Therapy. <i>Oncologist</i> , 2012, 17, 970-977.	3.7	9
113	Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2012, 82, 59-66.	1.9	29
114	Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14576-e14576.	1.6	0
115	Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma. <i>Anticancer Research</i> , 2012, 32, 4865-70.	1.1	11
116	Polymorphism in Epidermal Growth Factor Receptor Intron 1 Predicts Prognosis of Patients with Esophageal Cancer after Chemoradiation and Surgery. <i>Annals of Surgical Oncology</i> , 2011, 18, 2066-2073.	1.5	22
117	Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. <i>European Journal of Cancer</i> , 2011, 47, 1244-1257.	2.8	17
118	Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. <i>Journal of Hepatology</i> , 2011, 55, 858-865.	3.7	114
119	Induction Chemotherapy With Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by Concomitant Chemoradiotherapy in Patients With Locally Advanced Pancreatic Cancer: A Taiwan Cooperative Oncology Group Phase II Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e749-e757.	0.8	20
120	Retrospective Analysis of Outcome Differences in Preoperative Concurrent Chemoradiation With or Without Elective Nodal Irradiation for Esophageal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e593-e599.	0.8	42
121	t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1387-1395.	2.3	14
122	Increasing Incidence of Brain Metastasis in Patients with Advanced Hepatocellular Carcinoma in the Era of Antiangiogenic Targeted Therapy. <i>Oncologist</i> , 2011, 16, 82-86.	3.7	34
123	Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 155-161.	2.5	270
124	Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials. <i>Oncology</i> , 2011, 81, 143-150.	1.9	15
125	High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy. <i>Oncology</i> , 2011, 81, 98-103.	1.9	19
126	UMP/CMPK Is Not the Critical Enzyme in the Metabolism of Pyrimidine Ribonucleotide and Activation of Deoxycytidine Analogs in Human RKO Cells. <i>PLoS ONE</i> , 2011, 6, e19490.	2.5	6

#	ARTICLE	IF	CITATIONS
127	Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma. <i>Anticancer Research</i> , 2011, 31, 4007-11.	1.1	11
128	Modulation of human UMP/CMP kinase affects activation and cellular sensitivity of deoxycytidine analogs. <i>Biochemical Pharmacology</i> , 2010, 79, 381-388.	4.4	11
129	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 4590-4596.	4.1	154
130	Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. <i>Cancer Letters</i> , 2010, 298, 195-203.	7.2	20
131	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2010, 53, 126-131.	3.7	124
132	Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway. <i>Journal of Biological Chemistry</i> , 2009, 284, 11121-11133.	3.4	79
133	Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 442-448.	0.8	27
134	Association of Clinical and Dosimetric Factors with Postoperative Pulmonary Complications in Esophageal Cancer Patients Receiving Intensity-Modulated Radiation Therapy and Concurrent Chemotherapy Followed by Thoracic Esophagectomy. <i>Annals of Surgical Oncology</i> , 2009, 16, 1669-1677.	1.5	35
135	The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2009, 50, 518-527.	3.7	42
136	Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study. <i>Journal of Surgical Oncology</i> , 2008, 98, 34-41.	1.7	28
137	Systemic therapy for metastatic urothelial carcinoma. <i>BJU International</i> , 2008, 101, 795-803.	2.5	7
138	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment. <i>Lung Cancer</i> , 2008, 60, 215-221.	2.0	2
139	Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 659-661.	1.6	8
140	OSU-03012, a Novel Celecoxib Derivative, Induces Reactive Oxygen Species-Related Autophagy in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 9348-9357.	0.9	131
141	Intraperitoneal metastasis of hepatocellular carcinoma after spontaneous rupture: A case report. <i>World Journal of Gastroenterology</i> , 2008, 14, 3927.	3.3	33
142	Comparison of the Phosphorylation of 4'-Ethynyl 2',3'-Dihydro-3'-Deoxythymidine with That of Other Anti-Human Immunodeficiency Virus Thymidine Analogs. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1687-1693.	3.2	18
143	Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. <i>Anti-Cancer Drugs</i> , 2007, 18, 487-491.	1.4	37
144	Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. <i>Anti-Cancer Drugs</i> , 2007, 18, 703-708.	1.4	8

#	ARTICLE	IF	CITATIONS
145	Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens. <i>Urology</i> , 2007, 69, 479-484.	1.0	24
146	Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 207-213.	1.6	4
147	Esophageal Adenocarcinoma Arising from Barrett's Epithelium in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2007, 106, 664-668.	1.7	10
148	Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma. <i>Journal of Urology</i> , 2007, 177, 84-89.	0.4	24
149	CLINICAL STUDIES WITH CURCUMIN. , 2007, 595, 471-480.		308
150	Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 531-536.	2.8	7
151	Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. <i>Investigational New Drugs</i> , 2006, 25, 77-84.	2.6	107
152	Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma. <i>Cancer</i> , 2006, 106, 1269-1275.	4.1	23
153	A Pathway for Tumor Necrosis Factor- α -induced Bcl10 Nuclear Translocation. <i>Journal of Biological Chemistry</i> , 2006, 281, 167-175.	3.4	39
154	Phosphorylation of Cytidine, Deoxycytidine, and Their Analog Monophosphates by Human UMP/CMP Kinase Is Differentially Regulated by ATP and Magnesium. <i>Molecular Pharmacology</i> , 2005, 67, 806-814.	2.3	28
155	Survival Outcome of Inoperable Non-Small Cell Lung Cancer Patients Receiving Conventional Dose Epirubicin and Paclitaxel as First-Line Treatment. <i>Oncology</i> , 2005, 68, 350-355.	1.9	5
156	Inhibitors of Epidermoid Growth Factor Receptor Suppress Cell Growth and Enhance Chemosensitivity of Nasopharyngeal Cancer Cells in vitro. <i>Oncology</i> , 2005, 68, 538-547.	1.9	38
157	Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic Gastric Cancer. <i>Oncology</i> , 2005, 69, 88-95.	1.9	19
158	Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. <i>World Journal of Gastroenterology</i> , 2005, 11, 5283.	3.3	18
159	Synergistic Antitumor Activity of Troxacitabine and Camptothecin in Selected Human Cancer Cell Lines. <i>Molecular Pharmacology</i> , 2004, 66, 285-292.	2.3	11
160	Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2004, 51, 815-9.	0.5	6
161	Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy. <i>Anticancer Research</i> , 2004, 24, 3035-40.	1.1	43
162	Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. <i>Hepatology</i> , 2003, 37, 1320-1328.	7.3	256

#	ARTICLE	IF	CITATIONS
163	Prognostic Value of Multidrug Resistance 1, Glutathione-S-Transferase- γ and p53 in Advanced Nasopharyngeal Carcinoma Treated with Systemic Chemotherapy. <i>Oncology</i> , 2002, 62, 305-312.	1.9	29
164	The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells*. <i>Molecular Carcinogenesis</i> , 2002, 33, 137-145.	2.7	67
165	High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. <i>International Journal of Cancer</i> , 2002, 101, 519-525.	5.1	109
166	P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. <i>International Journal of Cancer</i> , 2002, 97, 451-457.	5.1	65
167	Pre-clinical and early-phase clinical studies of curcumin as chemopreventive agent for endemic cancers in Taiwan. <i>Japanese Journal of Cancer and Chemotherapy</i> , 2002, 29 Suppl 1, 194-200.	0.2	4
168	A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. <i>Anticancer Research</i> , 2002, 22, 3621-7.	1.1	7
169	Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin. <i>Anticancer Research</i> , 2002, 22, 4065-71.	1.1	10
170	Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Advanced Gastric Cancers. <i>Oncology</i> , 1997, 54, 275-280.	1.9	56
171	B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
172	Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma. <i>Esophagus</i> , 0, , .	1.9	0